Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity

JCI Insight

Volumn 2, Issue 22, 2017, Pages

  Chang, Shih Yu ^a   Weber, Elijah J ^a   Sidorenko, Viktoriya S ^b   Chapron, Alenka ^a   Yeung, Catherine K ^a,c   Gao, Chunying ^a   Mao, Qingcheng ^a   Shen, Danny ^a   Wang, Joanne ^a   Rosenquist, Thomas A ^b   Dickman, Kathleen G ^b   Neumann, Thomas ^d   Grollman, Arthur P ^b   Kelly, Edward J ^a   Himmelfarb, Jonathan ^c   Eaton, David L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Nortis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85040930807     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.95978     Document Type: Article

References (43)

1. Vanherweghem JL, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet. 1993;341(8842):387–391.
2. Grollman AP, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA. 2007;104(29):12129–12134.
3. Shibutani S, Dong H, Suzuki N, Ueda S, Miller F, Grollman AP. Selective toxicity of aristolochic acids I and II. Drug Metab Dispos. 2007;35(7):1217–1222.
4. Chen CH, et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci USA. 2012;109(21):8241–8246.
5. Jelaković B, et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int. 2012;81(6):559–567.
6. Sidorenko VS, et al. Bioactivation of the human carcinogen aristolochic acid. Carcinogenesis. 2014;35(8):1814–1822.
7. Hashimoto K, et al. Sulfotransferase-1A1-dependent bioactivation of aristolochic acid I and N-hydroxyaristolactam I in human cells. Carcinogenesis. 2016;37(7):647–655.
8. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760–772.
9. Weber EJ, et al. Development of a microphysiological model of human kidney proximal tubule function. Kidney Int. 2016;90(3):627–637.
10. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62(1):237–244.
11. Stiborová M, Martínek V, Frei E, Arlt VM, Schmeiser HH. Enzymes metabolizing aristolochic acid and their contribution to the development of aristolochic acid nephropathy and urothelial cancer. Curr Drug Metab. 2013;14(6):695–705.
12. Aleksunes LM, Goedken M, Manautou JE. Up-regulation of NAD(P)H quinone oxidoreductase 1 during human liver injury. World J Gastroenterol. 2006;12(12):1937–1940.
13. Bárta F, Levová K, Frei E, Schmeiser HH, Arlt VM, Stiborová M. The effect of aristolochic acid I on expression of NAD(P) H:quinone oxidoreductase in mice and rats-a comparative study. Mutat Res Genet Toxicol Environ Mutagen. 2014;768:1–7.
14. Arlt VM, et al. Impact of genetic modulation of SULT1A enzymes on DNA adduct formation by aristolochic acids and 3-nitro-benzanthrone. Arch Toxicol. 2017;91(4):1957–1975.
15. Meinl W, Pabel U, Osterloh-Quiroz M, Hengstler JG, Glatt H. Human sulphotransferases are involved in the activation of aristolochic acids and are expressed in renal target tissue. Int J Cancer. 2006;118(5):1090–1097.
16. Stiborová M, Mareš J, Frei E, Arlt VM, Martínek V, Schmeiser HH. The human carcinogen aristolochic acid i is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases. Environ Mol Mutagen. 2011;52(6):448–459.
17. Xue X, et al. Critical role of organic anion transporters 1 and 3 in kidney accumulation and toxicity of aristolochic acid I. Mol Pharm. 2011;8(6):2183–2192.
18. Bakhiya N, Arlt VM, Bahn A, Burckhardt G, Phillips DH, Glatt H. Molecular evidence for an involvement of organic anion transporters (OATs) in aristolochic acid nephropathy. Toxicology. 2009;264(1-2):74–79.
19. Ekaratanawong S, et al. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J Pharmacol Sci. 2004;94(3):297–304.
20. Rosenquist TA. Genetic loci that affect aristolochic acid-induced nephrotoxicity in the mouse. Am J Physiol Renal Physiol. 2011;300(6):F1360–F1367.
21. National Toxicology Program. NTP 12th Report on Carcinogens. Rep Carcinog. 2011;12:iii–499.
22. Sato N, et al. Acute nephrotoxicity of aristolochic acids in mice. J Pharm Pharmacol. 2004;56(2):221–229.
23. Hsieh SC, Lin IH, Tseng WL, Lee CH, Wang JD. Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003. Chin Med. 2008;3:13.
24. Vanherweghem LJ. Misuse of herbal remedies: the case of an outbreak of terminal renal failure in Belgium (Chinese herbs nephropathy). J Altern Complement Med. 1998;4(1):9–13.
25. Priestap HA, et al. Aristolochic acid I metabolism in the isolated perfused rat kidney. Chem Res Toxicol. 2012;25(1):130–139.
26. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology. 2008;245(3):194–205.
27. Lind C, Cadenas E, Hochstein P, Ernster L. DT-diaphorase: purification, properties, and function. Meth Enzymol. 1990;186:287–301.
28. Chen M, et al. Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity. Toxicol Sci. 2011;122(2):288–296.
29. Stiborová M, et al. The influence of dicoumarol on the bioactivation of the carcinogen aristolochic acid I in rats. Mutagenesis. 2014;29(3):189–200.
30. Pfau W, Pool-Zobel BL, von der Lieth CW, Wiessler M. The structural basis for the mutagenicity of aristolochic acid. Cancer Lett. 1990;55(1):7–11.
31. Riches Z, Stanley EL, Bloomer JC, Coughtrie MW. Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT “pie”. Drug Metab Dispos. 2009;37(11):2255–2261.
32. Krumbiegel G, Hallensleben J, Mennicke WH, Rittmann N, Roth HJ. Studies on the metabolism of aristolochic acids I and II. Xenobiotica. 1987;17(8):981–991.
33. Glatt H. Sulfation and sulfotransferases 4: bioactivation of mutagens via sulfation. FASEB J. 1997;11(5):314–321.
34. Gamage N, et al. Human sulfotransferases and their role in chemical metabolism. Toxicol Sci. 2006;90(1):5–22.
35. Skipper PL, Obiedzinski MW, Tannenbaum SR, Miller DW, Mitchum RK, Kadlubar FF. Identification of the major serum albumin adduct formed by 4-aminobiphenyl in vivo in rats. Cancer Res. 1985;45(10):5122–5127.
36. Ma L, Glatt HR. Albumin strongly prolongs the lifetime of chemically reactive sulphuric acid esters and affects their biological activities in the rat. Nova Acta Leopoldina. 2003;329:265–272.
37. Bendadani C, et al. Determination of sulfotransferase forms involved in the metabolic activation of the genotoxicant 1-hydroxymeth-ylpyrene using bacterially expressed enzymes and genetically modified mouse models. Chem Res Toxicol. 2014;27(6):1060–1069.
38. Slot AJ, Molinski SV, Cole SP. Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011;50(1):179–207.
39. Hagos Y, Wolff NA. Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity. Toxins (Basel). 2010;2(8):2055–2082.
40. Knudsen TB, et al. FutureTox II: in vitro data and in silico models for predictive toxicology. Toxicol Sci. 2015;143(2):256–267.
41. Wittwehr C, et al. How adverse outcome pathways can aid the development and use of computational prediction models for regulatory toxicology. Toxicol Sci. 2017;155(2):326–336.
42. Attaluri S, Iden CR, Bonala RR, Johnson F. Total synthesis of the aristolochic acids, their major metabolites, and related compounds. Chem Res Toxicol. 2014;27(7):1236–1242.
43. Chang SY, et al. Characterization of rat or human hepatocytes cultured in microphysiological systems (MPS) to identify hepatotoxicity. Toxicol In Vitro. 2017;40:170–183.